GSK (GSK) Company Report

Analyst Coverage

Research analysts who have asked questions during GSK earnings calls.

James Gordon

JPMorgan Chase & Co.

4 questions for GSK

Also covers: ARGX, AZN, GRFS

Graham Parry

Bank of America Corporation

3 questions for GSK

Also covers: GRFS, NVS, SNY

Rajan Sharma

Goldman Sachs Group, Inc.

3 questions for GSK

Also covers: ARGX, AUTL, AZN +6 more

Simon Baker

Redburn Atlantic

3 questions for GSK

Also covers: AUTL, AZN, BNTX +5 more

Emily Field

Barclays

2 questions for GSK

Also covers: AZN, GMAB, NVO +2 more

Kerry Holford

Berenberg

2 questions for GSK

Also covers: LLY, NVS, PFE

Peter Verdult

Citigroup Inc.

2 questions for GSK

Also covers: AZN, EVO, GMAB +4 more

Peter Welford

Jefferies

2 questions for GSK

Also covers: AZN, NVO, NVS +1 more

Richard Parkes

BNP Paribas Exane

2 questions for GSK

Also covers: AZN, NVO, NVS

Steve Scala

Cowen

2 questions for GSK

Also covers: ABBV, AZN, BMY +6 more

Jo Walton

UBS

1 question for GSK

Also covers: AZN, NVO, NVS +1 more

Justin Smith

Bernstein

1 question for GSK

Also covers: AZN, SCWO

Mark Purcell

Morgan Stanley

1 question for GSK

Also covers: AZN, NVS

Matthew Weston

UBS Group AG

1 question for GSK

Also covers: AZN, NVS, SNY

Michael Leuchten

Jefferies

1 question for GSK

Also covers: AZN, NVO, NVS +1 more

Sachin Jain

Bank of America

1 question for GSK

Also covers: AZN, GMAB, NVO +2 more

Sarita Kapila

Morgan Stanley

1 question for GSK

Also covers: AZN, SNY

Timothy Anderson

BofA Securities

1 question for GSK

Also covers: ABBV, AMGN, AZN +10 more

Latest news

Recent press releases and 8-K filings for GSK.

GSK to Acquire RAPT Therapeutics

GSK

M&A

New Projects/Investments

GSK has entered into a definitive agreement to acquire RAPT Therapeutics.
The acquisition is for an estimated aggregate equity value of $2.2 billion, with GSK paying $58.00 per share to RAPT Therapeutics shareholders.
The deal includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody in Phase IIb clinical development for prophylactic protection against food allergens.
The transaction is expected to close in the first quarter of 2026.

15 hours ago

6-K

GSK, Pfizer, and Shionogi Announce ViiV Healthcare Shareholding Restructuring

GSK

M&A

New Projects/Investments

Dividends

GSK, Pfizer, and Shionogi have agreed to restructure the shareholding of ViiV Healthcare, a global specialist HIV company.
Pfizer's 11.7% economic interest in ViiV Healthcare will be replaced by an investment from Shionogi, increasing Shionogi's holding to 21.7%.
GSK will maintain its 78.3% majority economic interest in ViiV Healthcare.
The transaction involves ViiV Healthcare issuing new shares to Shionogi for $2.125 billion, with Pfizer receiving $1.875 billion and GSK receiving a special dividend of $0.250 billion.
Completion is anticipated in the first quarter of 2026, pending regulatory clearances.

15 hours ago

6-K

GSK: Global Antibody Drug Conjugates Market Forecasts Strong Growth

GSK

New Projects/Investments

Product Launch

Revenue Acceleration/Inflection

The global antibody-drug conjugates (ADCs) market is projected to grow from USD 12.26 billion in 2024 to USD 32.11 billion by 2033, representing a compound annual growth rate (CAGR) of 10.49% from 2025 to 2033.
This significant expansion is primarily driven by the increasing prevalence of cancer and the escalating demand for targeted therapies that maximize efficacy and minimize systemic toxicity.
Key market drivers include recent advancements in targeted therapies, a surge in clinical trials, and strategic investments from pharmaceutical companies.
Regulatory approvals, such as Datroway in June 2025 and February 2025, and GSK's Blenrep in April 2025, underscore the growing validation and reliance on ADC therapies in the healthcare sector.

2 days ago

Press Release

GSK Highlights Strong R&D Momentum and Key Pipeline Advancements at J.P. Morgan Healthcare Conference

GSK

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

GSK's R&D pipeline achieved 13 positive Phase 3 readouts in 2024 and 5 out of 5 targeted approvals in 2025, with 15 scale launches projected to generate over $2 billion in peak sales by 2031.
R&D productivity has significantly improved, with end-to-end success rates more than doubling since 2018 and cycle times from last patient visit to first file in a major market more than halving from 2021 to 2024.
Key product advancements include the approval of Xtensia (depemokimab) as the first ultra-long-acting biologic for respiratory disease, showing a 70% reduction in severe exacerbations, and the launch of Blenrep for third-line multiple myeloma with expectations of greater than $3 billion in sales.
GSK is advancing Camlipixant for refractory chronic cough, with Phase 3 COM1 data transferred and COM2 expected to complete around mid-year, targeting a disease affecting 28 million patients globally with high unmet need.
In HIV, GSK expects Q4M PrEP data this year and will start Q4M treatment, with a third-generation integrase inhibitor (VH184) showing potential for a Q6M option and an improved resistance profile.

8 days ago

Transcript

GSK Highlights Strong Pipeline Momentum and Recent Approvals

GSK

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

GSK reported significant pipeline momentum with 13 positive Phase 3 readouts in 2024 and five approvals in 2025, leading to 15 scale launches with potential for greater than $2 billion peak sales by 2031.
Recent key approvals include Xtensia (depemokimab), the first ultra-long-acting biologic for respiratory disease, and an expanded COPD label for Nucala in mid-2025. Blenrep secured a label in the third-line multiple myeloma setting, with expectations for greater than $3 billion in sales.
The company's R&D productivity has notably improved, with end-to-end success rates more than doubling since 2018 and cycle times more than halving from 2021 to 2024.
Progress continues on the Bepi program for chronic hepatitis B, which met outcomes for the BWEL study , and the HIV pipeline, with Q4M PrEP data expected and Q4M treatment starting in 2026.

8 days ago

Transcript

GSK's Head of R&D Discusses Strong Pipeline Momentum and Key Drug Developments

GSK

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

GSK's Head of R&D reported 13 positive Phase 3 readouts in 2024 and five approvals in 2025, anticipating 15 scale launches with potential for greater than $2 billion peak sales by 2031.
R&D productivity has significantly improved, with end-to-end success rates more than doubling since 2018 and cycle times from last patient visit to first file more than halving from 2021 to 2024.
Xtensia (depemokimab), a recently approved ultra-long-acting biologic for respiratory disease, is seen by over 80% of pulmonologists as a potential standard of care.
Blenrep for multiple myeloma, approved in the US for third-line plus, is projected to achieve greater than $3 billion in sales, with potential for refiling in second and first line by end of 2028.
For camlipixant (refractory chronic cough), pooled Phase 3 data from CALM-1 and CALM-2 are expected around mid-2026, with a 15-20% improvement in daily coughing frequency considered clinically significant.

8 days ago

Transcript

Royalty Pharma Reports Record 2025 Performance and Provides 2026 Outlook

GSK

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

The royalty funding market reached a record $10 billion in 2025, with Royalty Pharma announcing $4.7 billion in transactions and maintaining approximately 40% market share.
Royalty Pharma is on track to meet its full-year 2025 guidance for 14%-16% top-line growth, with Portfolio Receipts projected to be between $3,200 and $3,250 million.
The company targets at least $4.7 billion in Portfolio Receipts by 2030, implying 9% or greater growth over the 2025-2030 period, and expects approximately $4.0 billion in Portfolio Cash Flow in 2030.
Key milestones anticipated in 2026 include pivotal data readouts for potential blockbuster therapies daraxonrasib, litifilimab, and pelacarsen, alongside expected FDA approval for zidesamtinib.

Jan 12, 2026, 12:15 PM

Press Release

GSK announces positive Phase III trial results for bepirovirsen

GSK

New Projects/Investments

GSK plc announced positive results from its two pivotal phase III trials, B-Well 1 and B-Well 2, for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B (CHB).
The trials met their primary endpoint, demonstrating a statistically significant and clinically meaningful functional cure rate for bepirovirsen.
Bepirovirsen, if approved, has the potential to become the first finite, six-month therapeutic option for CHB.
Global regulatory filings for bepirovirsen are planned to commence from Q1 2026.

Jan 7, 2026, 11:58 AM

6-K

GSK's Exdensur Approved in Japan for Severe Asthma and Chronic Rhinosinusitis

GSK

Product Launch

GSK announced on January 6, 2026, that its drug Exdensur (depemokimab) received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
Exdensur is the first and only ultra-long-acting biologic approved in Japan for these conditions, requiring only two doses a year.
The approval was based on data from the SWIFT and ANCHOR phase III trials, which demonstrated significant reductions in asthma exacerbations (e.g., 58% in SWIFT-1 and 48% in SWIFT-2) and improvements in nasal polyp size and nasal obstruction.
This Japanese approval marks the third regulatory milestone for depemokimab, following prior authorizations from the US Food and Drug Administration (FDA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Jan 6, 2026, 12:03 PM

6-K

GSK's Nucala Approved in China for COPD

GSK

Product Launch

New Projects/Investments

GSK's Nucala (mepolizumab) has been approved by China's National Medical Products Administration (NMPA) as an add-on maintenance treatment for adult patients with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD) characterized by raised blood eosinophils.
Nucala is the first and only monthly biologic approved in China for COPD, evaluated in patients with a blood eosinophil count (BEC) starting as low as 150 cells/µL.
The approval is based on positive MATINEE and METREX phase III trials, which demonstrated a clinically meaningful and statistically significant reduction in the annualised rate of moderate/severe exacerbations.
China faces a substantial COPD burden, with approximately 100 million people affected and over 30% of global COPD mortality occurring in the country.